Antiarrhythmic Drug Therapy in Patients with Preexcitation Syndromes

  • Eric N. Prystowsky

Abstract

Patients with preexcitation syndromes may exhibit a variety of tachyarrhythmias [1]. The accessory pathway(s) associated with a particular preexcitation syndrome may be used as part of an atrioventricular (AV) reentrant tachycardia circuit (i.e., orthodromic or antidromic reciprocating tachycardia), or in certain arrhythmias such as atrial fibrillation the accessory pathway may not be needed to sustain tachycardia but is utilized to conduct impulses to the ventricle. Patients with preexcitation syndrome also may have tachycardias that do not involve conduction over the accessory pathway, such as ventricular tachycardia [2].

Keywords

Adenosine Cardiol Propranolol Lidocaine Digoxin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Prystowsky EN, Miles WM, Heger JJ, Zipes DP: Preexcitation syndromes. Med. Clin. N. A. 68: 831, 1984Google Scholar
  2. 2.
    Lloyd EA, Hauer RN, Zipes DP, Heger JJ, Prystowsky EN: Syncope and ventricular tachy¬cardia in patients with ventricular preexcitation. Am. J. Cardiol. 52: 79, 1983.PubMedCrossRefGoogle Scholar
  3. 3.
    Dreifus LS, Haiat R, Watanabe Y, Arriaga J, Reitman N: Ventricular fibrillation. A possible mechanism of sudden death in patients with Wolff-Parkinson-White syndrome. Circulation 43: 520, 1971.PubMedGoogle Scholar
  4. 4.
    Klein GJ, Bashore TM, Sellers TD, Pritchett ELC, Smith WM, Gallagher JJ: Ventricular fibrillation in the Wolff-Parkinson-White syn¬drome. N. Engl. J. Med. 301: 1080, 1979.PubMedCrossRefGoogle Scholar
  5. 5.
    Wellens HJ, Durrer D: Wolff-Parkinson-White syndrome and atrial fibrillation. Relation be¬tween refractory period of accessory pathway and ventricular rate during atrial fibrillation. Am. J. Cardiol. 34: 777, 1974.PubMedCrossRefGoogle Scholar
  6. 6.
    Tonkin AM, Miller HC, Svenson RH, Wallace AG, Gallagher JJ: Refractory periods of the accessory pathway in the Wolff-Parkinson¬White syndrome. Circulation 52: 563, 1975.PubMedGoogle Scholar
  7. 7.
    Wellens HJJ, Braat S, Brugada P, Gorgels APM, Bar FW: Use of procainamide in patients with the Wolff-Parkinson-White syndrome to dis¬close a short refractory period of the accessory pathway. Am. J. Cardiol. 50: 1087, 1982.PubMedCrossRefGoogle Scholar
  8. 8.
    Klein GJ, Gulamhusein SS: Intermittent pre-excitation in the Wolff-Parkinson-White syn¬drome. Am. J. Cardiol. 52: 292, 1983.PubMedCrossRefGoogle Scholar
  9. 9.
    Rowland E, Curry P, Fox K, Krikler D: Relation between atrioventricular pathways and ventricu¬lar response during atrial fibrillation and flutter. Br. Heart J. 45: 83, 1981.PubMedCrossRefGoogle Scholar
  10. 10.
    German LD, Gallagher JJ, Broughton A, Guan¬nieri T, Trantham JL: Effects of exercise and isoproterenol during atrial fibrillation in patients with Wolff-Parkinson-White syndrome. Am. J. Cardiol. 51: 1203, 1983.PubMedCrossRefGoogle Scholar
  11. 11.
    Cosio FG, Benson DW Jr, Anderson RW, Hes¬sion WT, Pritzker MR, Kreit JM, Benditt DG: Onset of atrial fibrillation during antidromic tachycardia: Association with sudden cardiac arrest and ventricular fibrillation in a patient with Wolff-Parkinson-White syndrome. Am. J. Car¬diol. 50: 353, 1982.CrossRefGoogle Scholar
  12. 12.
    Prystowsky EN: Pharmacologic therapy of tachyarrhythmias in patients with Wolff¬Parkinson-White syndrome. Herz 8: 133, 1983.PubMedGoogle Scholar
  13. 13.
    Jedeikin R, Gillette PC, Garson A, Porter CJ, Beder S, Baron P, Zinner AJ III: Effect of ouabain on the anterograde effective refractory period of accessory atrioventricular connections in children. J. Am. Coll. Cardiol. 1: 869, 1983.PubMedCrossRefGoogle Scholar
  14. 14.
    Sellers TD, Bashore TM, Gallagher JJ: Digitalis in the preexcitation syndrome. Analysis during atrial fibrillation. Circulation 56: 260, 1977.PubMedGoogle Scholar
  15. 15.
    Wellens HJJ, Durrer D: Effect of digitalis on atrioventricular conduction and circus-move¬ment tachycardia in patients with Wolff¬Parkinson-White syndrome. Circulation 47: 1229, 1973.PubMedGoogle Scholar
  16. 16.
    Deal BJ, Keane JF, Gillette PC, Garson A: Wolff-Parkinson-White syndrome and supra-ventricular tachycardia during infancy: manage¬ment and follow-up. J. Am. Coll. Cardiol. 5: 130, 1985.PubMedCrossRefGoogle Scholar
  17. 17.
    Damato AN, Caracta AR, Akhtar M, Lau SH: The effects of commonly used cardiovascular drugs on AV conduction and refractoriness. In His Bundle Electrocardiography and Clinical Electrophysiology, Narula OS (ed.), Philadelphia, Davis Publishing Co., 1975, pp. 105–125.Google Scholar
  18. 18.
    Dhingra RC, Palileo EV, Strasberg B, Swiryn S, Bauernfeind R, Wyndham C, Rosen KM: Elec¬trophysiologic effects of ouabain in patients with preexcitation and circus movement tachycardia. Am. J. Cardiol. 47: 139, 1981.PubMedCrossRefGoogle Scholar
  19. 19.
    Vrhovac B, Bakran I, Durakovic Z, Gjurasin M, Francetic I, Mohacek I: The effect of propra¬nolol, prindolol, practolol and verapamil versus placebo on exercise induced tachycardia in pa¬tients with ventricular preexcitation. Int. J. Clin. Pharmacol. 14: 132, 1976.Google Scholar
  20. 20.
    Hombach V, Braun V, Hopp H-W, Gil-Sanchez D, Behrenbeck DW, Tauchert M, Hilger HH: Antiarrhythmic effects of acute beta-blockade with atenolol on supraventricular tachycardias at rest and during exercise. Klin. Wochenschr. 59: 123, 1981.PubMedCrossRefGoogle Scholar
  21. 21.
    Gmeiner R, Ng CK: Metoprolol in the treatment and prophylaxis of paroxysmal reentrant supra-ventricular tachycardia. J. Cardiovasc. Phar¬macol. 4: 5, 1982.CrossRefGoogle Scholar
  22. 22.
    Skale BT, Heger JJ, Zipes DP, Prystowsky EN: Timolol: electrophysiologic and antiarrhythmic evaluation in ventricular and supraventricular tachycardia. (Submitted for publication.)Google Scholar
  23. 23.
    Chang M-S, Sung RJ, Tai T-Y, Lin S-L, Liu P-H, Chiang BN: Nadolol and supraventricular tachy¬cardia: an electrophysiologic study. J. Am. Coll. Cardiol. 2 (5): 894, 1983.PubMedCrossRefGoogle Scholar
  24. 24.
    Prystowsky EN, Jackman WM, Rinkenberger RL, Heger JJ, Zipes DP: Effect of autonomic blockade on ventricular refractoriness and atrioventricular nodal conduction in man. Evi¬dence supporting a direct cholinergic action on ventricular muscle refractoriness. Circ. Res. 49: 511, 1981.PubMedGoogle Scholar
  25. 25.
    Berkowitz WD, Wit AL, Lau SH, Steiner C, Damato AN: The effects of propranolol on cardiac conduction. Circulation 40: 855, 1969.Google Scholar
  26. 26.
    Denes P, Cummings JM, Simpson R, Wu D, Amta-y-Leon R, Dhingra R, Rosen KM: Effects of propranolol on anomalous pathway refractori¬ness and circus movement tachycardias in patients with preexcitation. Am. J. Cardiol. 41: 1061, 1978.PubMedCrossRefGoogle Scholar
  27. 27.
    Barrett PA, Jordan JL, Mandel WJ, Yamaguchi I, Laks MM: The electrophysiologic effects of in¬travenous propranolol in the Wolff-Parkinson¬White syndrome. Am. Heart J. 98: 213, 1979.PubMedCrossRefGoogle Scholar
  28. 28.
    Przybylski J, Chiale PA, Halpern S, Nau GJ, Elizari MV, Rosenbaum MB: Unmasking of ventricular preexcitation by vagal stimulation or isoproterenol administration. Circulation 61: 1030, 1980.PubMedGoogle Scholar
  29. 29.
    Wellens HJJ, Brugada P, Roy D, Weiss J, Bar FW: Effect of isoproterenol on the antegrade refractory period of the accessory pathway in patients with the Wolff-Parkinson-White syn¬drome. Am. J. Cardiol. 50: 180, 1982.PubMedCrossRefGoogle Scholar
  30. 30.
    Wit AL, Cranefield PF: Effect of verapamil on the sinoatrial and atrioventricular nodes of the rabbit and the mechanism by which it arrests reentrant atrioventricular nodal tachycardia. Circ. Res. 35: 413, 1974.PubMedGoogle Scholar
  31. 31.
    Zipes DP, Fischer JC: Effects of agents which inhibit the slow channel on sinus node auto¬maticity and atrioventricular conduction in the dog. Circ. Res. 34: 124, 1974.Google Scholar
  32. 32.
    Zipes DP, Mendez C: Action of manganese ion and tetrodotoxin on atrioventricular nodal trans-membrane potentials in isolated rabbit hearts. Circ. Res. 32: 447, 1973.PubMedGoogle Scholar
  33. 33.
    Singh BN, Vaughan Williams EM: A fourth class of antidysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial, and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc. Res. 6: 109, 1972.PubMedCrossRefGoogle Scholar
  34. 34.
    Klein GJ, Gulamhusein S, Prystowsky EN, Car¬ruthers SG, Donner AP, Ko PT: Comparison of the electrophysiological effects of intravenous and oral verapamil in patients with paroxysmal supraventricular tachycardia. Am. J. Cardiol. 49: 117, 1982.PubMedCrossRefGoogle Scholar
  35. 35.
    Krikler DM, Spurrell RAJ: Verapamil in the treatment of paroxysmal supraventricular tachy¬cardia. Postgrad. Med. 50: 447, 1974.CrossRefGoogle Scholar
  36. 36.
    Rinkenberger RL, Prystowsky EN, Heger JJ, Troup PJ, Jackman WM, Zipes DP: Effects of IV and chronic oral verapamil administration in patients with a variety of supraventricular tachyarrhythmias. Circulation 62: 996, 1980.PubMedGoogle Scholar
  37. 37.
    Schamroth L, Krikler DM, Garrett C. Immediate effects of intravenous verapamil in cardiac arrhythmias. Br. Med. J. 1: 660, 1972.PubMedCrossRefGoogle Scholar
  38. 38.
    Spurrell RAJ, Krikler DM, Sowton’E: Effects of verapamil on electrophysiological properties of anomalous atrioventricular connexion in Wolff¬Parkinson-White syndrome. Br. Heart J. 36: 256, 1974.PubMedCrossRefGoogle Scholar
  39. 39.
    Wellens HJJ, Tan SL, Bar FW, Duren DR, Lie KI, Dohmen HM: Effect of verapamil studied by programmed electrical stimulation of the heart in patients with paroxysmal reentrant supra-ventricular tachycardia. Br. Heart J. 39: 1058, 1977.PubMedCrossRefGoogle Scholar
  40. 40.
    Hamer A, Peter T, Platt M, Mandel WJ: Effects of verapamil on supraventricular tachycardia in patients with overt and concealed Wolff¬Parkinson-White syndrome. Am. Heart J. 101: 600, 1981.PubMedCrossRefGoogle Scholar
  41. 41.
    Prystowsky EN, Gilmour RF Jr: Role of slow channel blockers in the treatment of arrhythmias: Basic considerations and clinical applications. In Pharmacological Treatment of Cardiovascular Diseases, Kostis JB, Defelice EA (eds.), New York, Medical Examination Publishing Co., 1985 (in press).Google Scholar
  42. 42.
    Rozanski JJ, Zaman L, Castellanos A: Elec¬trophysiologic effects of Diltiazem Hydro chloride on supraventricular tachycardia. Am. J. Cardiol. 49: 621, 1982.PubMedCrossRefGoogle Scholar
  43. 43.
    Yeh SJ, Kou HC, Liov FC, Hung JS, Wu D: Effects of oral Diltiazem in paroxysmal supra-ventricular tachycardia. Am. J. Cardiol. 52: 271, 1983.PubMedCrossRefGoogle Scholar
  44. 44.
    Betriu A, Chaitman BR, Bourassa MG, Brevers G, School JM, Bruneau P, Gagne P, Chabot M: Beneficial effect of intravenous Diltiazem in the acute management of paroxysmal supraventric¬ular tachyarrhythmias. Circulation 67: 88, 1983.PubMedCrossRefGoogle Scholar
  45. 45.
    Prystowsky EN: Electrophysiologic and anti-arrhythmic properties of bepridil. Am. J. Car¬diol. 55 (7): 59C, 1985.CrossRefGoogle Scholar
  46. 46.
    Rowland E, McKenna W, Krikler DM: Com¬parative electrophysiological effects of novel antiarrhythmic drug, bepridil. (Abstract.) Br. Heart J. 48: 87, 1982.CrossRefGoogle Scholar
  47. 47.
    Gulamhusein S, Ko P, Carruthers SG, Klein GJ: Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 65: 348, 1982.PubMedCrossRefGoogle Scholar
  48. 48.
    Petri H, Kafka W, Hall D, Rudolph W: Potential acceleration of the ventricular rate in Wolff¬Parkinson-White syndrome with atrial fibrilla¬tion after verapamil. (Abstract.) Circulation 62: 262, 1980.Google Scholar
  49. 49.
    Harper RW, Whitford E, Middlebrook K, Federman J, Anderson S, Pitt A: Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome. Am. J. Car¬diol. 50: 56, 1982.Google Scholar
  50. 50.
    Petri H, Kafka W, Rudolph W: Discrepant effects of oral and intravenous verapamil on A-V conduction in patients with ventricular preexcita¬tion and atrial fibrillation. Herz 8: 144, 1983.PubMedGoogle Scholar
  51. 51.
    Puech P, Sassine A, Munoz A, Masse C, Zettelmaier F, Leenhardt A, Yoshimura H: Electrophysiologic effects of purines; Clinical applications. In Cardiac Electrophysiology and Arrhythmias, New York, Grune and Stratton, 1985, pp. 443–450.Google Scholar
  52. 52.
    DiMarco JP, Sellers TD, Berne RM, West GA, Belardinelli L: Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Cir¬culation 68: 1254, 1983.CrossRefGoogle Scholar
  53. 53.
    Belhassen B, Pelleg A: Acute management of paroxysmal supraventricular tachycardia: Vera¬pamil, adenosine triphosphate or adenosine? Am. J. Cardiol. 54: 225, 1984.PubMedCrossRefGoogle Scholar
  54. 54.
    Wellens HJJ, Bar FW, Dassen WRM, Brugada P, Vanagt EJ, Farre J: Effect of drugs in the Wolff¬Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway. Am. J. Cardiol. 46: 665, 1980.PubMedCrossRefGoogle Scholar
  55. 55.
    Rosen KM, Barwolf C, Ehsani A, Rahimtoola SH: Effects of lidocaine and propranolol on the normal and anomalous pathways with preexcita¬tion. Am. J. Cardiol. 30: 801, 1972.PubMedCrossRefGoogle Scholar
  56. 56.
    Josephson ME, Kastor JA, Ketchen JG: III: Lidocaine in Wolff-Parkinson-White syndrome with atrial fibrillation. Ann. Intern. Med. 84: 44, 1976.PubMedGoogle Scholar
  57. 57.
    Barrett PA, Laks MM, Mandel WJ, Yamaguchi I: The electrophysiologic effects of intravenous lidocaine in the Wolff-Parkinson-White syn¬drome. Am. Heart J. 100: 23, 1980.PubMedCrossRefGoogle Scholar
  58. 58.
    Akhtar M, Gilbert CJ, Shenasa M: Effect of lidocaine on atrioventricular response via the accessory pathway in patients with Wolff¬Parkinson-White syndrome. Circulation 63: 435, 1981.PubMedCrossRefGoogle Scholar
  59. 59.
    Puech P, Latour H, Hertault J, Grolleau R: L’ajmaline injectable dans les tachycardies paroxystiques et le syndrome de Wolff¬Parkinson-White. Comparison avec le procaina¬mide. Arch. Mal Coeur 2: 897, 1964.Google Scholar
  60. 60.
    Selarovsky S, Kracoff OH, Strasberg B, Lewin RF, Agmon J: Paroxysmal atrial flutter and fibrillation associated with preexcitation syn¬drome: treatment with ajmaline. Am. J. Cardiol. 48: 929, 1981.CrossRefGoogle Scholar
  61. 61.
    Wellens HJJ, Bar FW, Gorgels AP, Vanagt EJ: Use of ajmaline in patients with the Wolff¬Parkinson-White syndrome to disclose short refractory period of the accessory pathway. Am. J. Cardiol. 45: 130, 1980.PubMedCrossRefGoogle Scholar
  62. 62.
    Wellens HJJ, Durrer D: Effect of procaine amide, quinidine, and ajmaline in the Wolff¬Parkinson-White syndrome. Circulation 50: 114, 1974.PubMedGoogle Scholar
  63. 63.
    Chang M-S, Tai D-Y, Chiang BN, Sung RJ: Efficacy and antiarrhythmic mechanism of N¬propyl Ajmaline in the treatment of paroxysmal supraventricular tachycardia. J. Am. Coll. Car¬diol. 5: 479, 1985.Google Scholar
  64. 64.
    Wellens HJJ, Bar FW, Vanagt EJ: Death after ajmaline administration. Am. J. Cardiol. 45: 905, 1980.PubMedCrossRefGoogle Scholar
  65. 65.
    Kerr CR, Prystowsky EN, Smith WM, Cook L, Gallagher JJ: Electrophysiologic effects of diso¬pyramide phosphate in patients with Wolff¬Parkinson-White syndrome. Circulation 65: 869, 1982.PubMedCrossRefGoogle Scholar
  66. 66.
    Mandel WJ, Laks MM, Obayashi K, Hayakawa H, Daley W: The Wolff-Parkinson-White syn¬drome: Pharmacologic effects of procainamide. Am. Heart J. 90: 744, 1975.PubMedCrossRefGoogle Scholar
  67. 67.
    Sellers TD Jr, Campbell RWF, Bashore TM, Gallagher JJ: Effects of procainamide and quini¬dine sulfate in the Wolff-Parkinson-White syn¬drome. Circulation 55: 15, 1977.PubMedGoogle Scholar
  68. 68.
    Spurrell RAJ, Thorburn CW, Camm J, Sowton E, Deuchar DC: Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson¬White syndrome. Br. Heart J. 37: 861, 1975.PubMedCrossRefGoogle Scholar
  69. 69.
    Bennett DH: Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Chest 74: 624, 1978.PubMedCrossRefGoogle Scholar
  70. 70.
    Benditt DG, Pool-Schneider S, Dunnigan A, Gornick CC, Benson DW Jr: Suppression of paroxysmal supraventricular tachyarrhythmias with intravenous mexiletine. (Abstract.) PACE 8: 302, 1985.Google Scholar
  71. 71.
    Touboul P, Gressard A, Kirkorian G, Atallah G: Effects of mexiletine in the Wolff-Parkinson¬White syndrome. Arch. Mal Coeur 74: 1315, 1981.PubMedGoogle Scholar
  72. 72.
    Jackman WM, Zipes DP, Naccarelli GV, Rinkenberger RL, Heger JJ, Prystowsky EN: Electrophysiology of oral encainide. Am. J. Cardiol. 49: 1270, 1982.PubMedCrossRefGoogle Scholar
  73. 73.
    Prystowsky EN, Klein GH, Rinkenberger RL, Heger JJ, Naccarelli GV, Zipes DP: Clinical efficacy and electrophysiologic effects of en¬cainide in patients with the Wolff-Parkinson¬White syndrome. Circulation 69: 278, 1984.PubMedCrossRefGoogle Scholar
  74. 74.
    Kunze K-P, Kuck K-H, Schluter M, Kuch B, Bleifeld W: Electrophysiologic and clinical effects of intravenous and oral encainide in acces¬sory atrioventricular pathway. Am. J. Cardiol. 54: 323, 1984.PubMedCrossRefGoogle Scholar
  75. 75.
    Abdollah H, Brugada P, Green M, Wehr M, Wellens HJJ, with the technical assistance of Paulussen G: Clinical efficacy and electrophys¬iologic effects of intravenous and oral encainide in patients with accessory atrioventricular path¬ways and supraventricular arrhythmias. Am. J. Cardiol. 54: 544, 1984.PubMedCrossRefGoogle Scholar
  76. 76.
    Heger JJ, Prystowsky EN, Jackman WM, Nac¬carelli GV, Warfel KA, Rinkenberger RL, Zipes DP. Amiodarone: clinical efficacy and elec¬trophysiology during long-term therapy for re¬current ventricular tachycardia or ventricular fibrillation. N. Engl. J. Med. 305: 539, 1981.PubMedCrossRefGoogle Scholar
  77. 77.
    Ward DE, Camm AJ Spurrell RAJ: Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. Br. Heart J. 44: 91, 1980.PubMedCrossRefGoogle Scholar
  78. 78.
    Yee KG, Heger JJ, Prystowsky EN, Miles WM, Zipes DP: Predictors of clinical efficacy for amiodarone in supraventricular tachyarrhyth¬mias. (Abstract.) Circulation 70: II - 438, 1984.Google Scholar
  79. 79.
    Chamberlain DA, Clark ANG: Atrial fibrillation complicating Wolff-Parkinson-White syndrome treated with amiodarone. Br. Med. J. 2: 1519, 1977.CrossRefGoogle Scholar
  80. 80.
    Rosenbaum MB, Chiate PA, Ryba D, Elizari MV: Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am. J. Cardiol. 34: 215, 1974.PubMedCrossRefGoogle Scholar
  81. 81.
    Rowland E, Krikler DM: Electrophysiological assessment of amiodarone in treatment of resis tant supraventricular arrhythmias. Br. Heart J. 44: 82, 1980.PubMedCrossRefGoogle Scholar
  82. 82.
    Touboul P, Porte J, Huerta F, Delahaye J-P: Effets electrophysiologiques de l’amiodarone dans le syndrome de Wolff-Parkinson-White. Arch. Mal Coeur 69: 855, 1976.PubMedGoogle Scholar
  83. 83.
    Waleffe A, Bruninx P, Kulbertus HE: Effects of amiodarone studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventricular tachy¬cardia. J. Electrocardiol. 11: 253, 1978.PubMedCrossRefGoogle Scholar
  84. 84.
    Wellens HJJ, Lie KI, Bar FW, Wesdrop JC, Dohmen HJ, Duren DR, Durrer D: Effect of amiodarone in Wolff-Parkinson-White syn¬drome. Am. J. Cardiol. 38: 189, 1976.PubMedCrossRefGoogle Scholar
  85. 85.
    Kappenberger LJ, Fromer MA, Steinbrunn W, Shenasa M: Efficacy of amiodarone in the Wolff¬Parkinson-White syndrome with rapid ventric¬ular response via accessory pathway during atrial fibrillation. Am. J. Cardiol. 54: 330, 1984.PubMedCrossRefGoogle Scholar
  86. 86.
    Chilson DA, Heger JJ, Zipes DP, Browne KF, Prystowsky EN: Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia. J. Am. Coll. Cardiol. 5 (6): 1407, 1985.PubMedCrossRefGoogle Scholar
  87. 87.
    Breithardt G, Borggrefe M, Wiebringhaus E, Seipel L: Effect of propafenone in the Wolff Parkinson-White syndrome: Electrophysiologic findings and long-term follow-up. Am. J. Car¬diol. 54: 29D, 1984.Google Scholar
  88. 88.
    Waleffe A, Mary-Rabine L, de Rijbel R, Soyeur D, Legrand V, Kulbertus HE: Electrophysiolo¬gical effects of propafenone studied with prog¬rammed electrical stimulation of the heart in patients with recurrent paroxysmal supra-ventricular tachycardia. Eur. Heart J. 2: 345, 1981.PubMedGoogle Scholar
  89. 89.
    Neuss H, Buss J, Schlepper M, Berthold R, Mitrovic V, Kramer A, Musial J: Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson¬White syndrome. Eur. Heart J. 4: 347, 1983.PubMedGoogle Scholar
  90. 90.
    Bennett DH: Acute prolongation of myocardial refractoriness by sotalol. Br. Heart J. 47: 521, 1982.PubMedCrossRefGoogle Scholar
  91. 91.
    Nathan AW, Hellestrand KJ, Bexton RS, Ward DE, Spurrell RAJ, Camm AJ: Electrophysiolo¬gical effects of sotalol — just another beta blocker? Br. Heart J. 47: 515, 1982.PubMedCrossRefGoogle Scholar
  92. 92.
    Kasper W, Treese N, Meinertz T, Jahnchen E, Pop T: Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff Parkinson-White syndrome. Am. J. Cardiol. 51: 1618, 1983.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing 1986

Authors and Affiliations

  • Eric N. Prystowsky

There are no affiliations available

Personalised recommendations